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colorectal cancer; CRDs, carbohydrate recognition domains; EGFR, epidermal 
growth factor receptor; EPCAM, epithelial cell adhesion molecule; KRAS, Kirsten rat 
sarcoma viral oncogene homolog; KRASmut: KRAS mutant; LAMP2, lysosomal 
associated membrane protein 2; LC3B/MAP1LC3B, microtubule-associated protein 1 
light chain 3 B; LGALS9/galectin-9, lectin, galactose-binding, soluble, 9; 
(serine/threonine kinase); PRKC, protein kinase C; PS, phosphatidylserine; PtdIns3K, 
class III phosphatidylinositol 3-kinase; RAF1/CRAF, Raf-1 proto-oncogene, 
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ribosomal protein S6 kinase, 70kDa, polypeptide 1; SQSTM1/p62, sequestosome 1; 
TNFSF10/TRAIL, tumor necrosis factor (ligand) superfamily, member 10. 
Abstract 
Oncogenic mutation of KRAS (Kirsten rat sarcoma viral oncogene homolog) in 
colorectal cancer (CRC) confers resistance to both chemotherapy and EGFR 
(epidermal growth factor receptor)-targeted therapy. We uncovered that KRAS 
mutant (KRASmut) CRC is uniquely sensitive to treatment with recombinant 
LGALS9/Galectin-9 (rLGALS9), a recently established regulator of epithelial polarity. 
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Upon treatment of CRC cells, rLGALS9 rapidly internalizes via early- and late-
endosomes and accumulates in the lysosomal compartment. Treatment with 
rLGALS9 is accompanied by induction of frustrated autophagy in KRASmut CRC, but 
not in CRC with BRAF (B-Raf proto-oncogene, serine/threonine kinase) mutations 
(BRAFmut). In KRASmut CRC, rLGALS9 acts as a lysosomal inhibitor that inhibits 
autophagosome-lysosome fusion, leading to autophagosome accumulation, 
excessive lysosomal swelling and cell death. This antitumor activity of rLGALS9 
directly correlates with elevated basal autophagic flux in KRASmut cancer cells. Thus, 
rLGALS9 has potent antitumor activity towards refractory KRASmut CRC cells that 
may be exploitable for therapeutic use. 
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Introduction 
Oncogenic mutation of KRAS (Kirsten rat sarcoma viral oncogene homolog) is found 
in 30-45% of all colorectal cancer (CRC) patients and associates with poor 
prognosis.1 Specifically, KRAS mutated CRC often poorly responds to chemotherapy 
due to an increased drug resistance and is insensitive to EGFR (epidermal growth 
factor receptor)-targeted therapeutics.1,2 Unfortunately, the RAS pathway has proven 
an elusive target for cancer therapy, with the development of effective drugs targeting 
RAS being difficult.3 Further, targeting of downstream effectors, such as RAF1, has 
yielded agents with only modest clinical activity in metastatic CRC patients that is 
associated with substantial off-target toxicity.4 Therefore, the development of new 
therapeutic options for this large subset of refractory CRC patients is urgently 
needed.  
Oncogenic KRAS mutation (KRASmut) disrupts apical-basolateral polarity and 
prevents the formation of tight junctions in colon epithelial cells.5 Loss of cellular 
polarity is a key factor in the acquisition of metastatic potential and may represent an 
Achilles’ heel of epithelial cancers (reviewed in 6,7). Of note, selected members of 
the galectin family of carbohydrate-binding proteins have recently been recognized 
as important regulators of epithelial polarity and endocytosis. For instance, 
LGALS3/Galectin-3 maintains apical polarity by regulating clathrin-independent 
endocytosis of cargo proteins,8,9,10 whereas LGALS8/galectin-8 steers endocytic and 
autophagic removal of bacteria.11 
Recently, LGALS9/Galectin-9 (lectin, galactose-binding, soluble, 9) has also 
emerged as an important regulator of endocytosis and polarity in epithelial cells.12,13 
In epithelial monolayers, LGALS9 undergoes a cyclical process of endosomal 
internalization and rerouting to the apical surface via the trans-Golgi network and 
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recycling endosomes.12,13 Upon targeted deletion of LGALS9 expression in these 
monolayers, polarity is lost and apical and basolateral proteins mislocalize.12,13 Loss 
of expression of LGALS9 is also associated with metastatic progression in various 
epithelial cancers, including breast and colorectal cancer.14,15,16,17,18 Taken together, 
this suggests that loss of LGALS9 promotes a metastatic tumor phenotype. 
Conversely, treatment of LGALS9 deficient monolayers with exogenous recombinant 
LGALS9 (rLGALS9) restores epithelial polarity.12,13 Further, rLGALS9 treatment of 
murine syngeneic colorectal carcinoma inhibits the formation of lung metastases.19 
Thus, treatment with exogenous rLGALS9 could potentially target the postulated 
Achilles’ heel of epithelial cancers. 
Here, we show that in colorectal carcinoma cells, exogenous rLGALS9 is 
rapidly internalized via clathrin- and PRKC (protein kinase C)-, RAF1 (Raf-1 proto-
oncogene, serine/threonine kinase)-, MAP2K1 (mitogen-activated protein kinase 
kinase 1)-dependent endocytosis leading to lysosomal accumulation of rLGALS9. 
This triggers cell death in refractory KRAS mutant cancer cells, characterized by 
lysosomal swelling and a halt in the execution of autophagy at the stage of 
autophagosome-lysosome fusion. Thus, rLGALS9 is a lysosomal inhibitor with potent 
cytotoxic activity towards refractory KRAS mutant colon carcinoma cells that may be 
exploitable for therapeutic use. 
Results  
rLGALS9 internalizes into the lysosomal compartment in nonpolarized 
cells 
LGALS9 maintains apical polarity in established epithelial monolayers through a 
cyclical process of LGALS9 internalization into early endosomes, routing to the trans-
Golgi network, and a resurfacing to the apical cell surface via recycling endosomes.12 
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In order to follow the routing of LGALS9 in settings of disturbed polarity, nonpolarized 
MDCK cells and DLD-1 colorectal cancer cells were treated with rLGALS9/rGAL9(0), 
a previously reported recombinant form of LGALS9 containing a truncated linker for 
improved stability.20 Surface binding of fluorescently labeled recombinant rLGALS9 
was detected within 1 min, followed by rapid internalization (Fig. 1A). Initially, 
internalized rLGALS9 was localized in close proximity to the cell membrane, but at 
later time points accumulated in enlarged vesicles more centrally located in the 
cytoplasm (Fig. 1A). This internalization of rLGALS9 was dependent on its 
carbohydrate recognition domains (CRDs), since the CRD-blocking sugar α-lactose, 
but not the irrelevant sugar sucrose, abrogated rLGALS9 internalization (Fig. 1A). 
The subcellular localization of rLGALS9 was determined using a panel of cell 
compartmental markers, which demonstrated that on DLD-1 cells rLGALS9 initially 
colocalized with the cell surface marker EPCAM (epithelial cell adhesion molecule) 
(Fig. 1B; t=5 min). In time, this was followed by colocalization of rLGALS9 with the 
GFP-tagged early endosome marker RAB5A (Fig. 1C; t=30 min), with the GFP-
tagged late endosome marker RAB7A (Fig. 1D; t=1 h) and with the lysosomal marker 
LAMP2 (lysosomal-associated membrane protein 2) Fig. 1E; t=24 h). Similar 
intracellular localization of rLGALS9 was observed for MDCK (Fig. S1A-C). 
Colocalization analysis (using Pearson’s correlation coefficient-Rr) confirmed that 
rLGALS9 very rapidly disappeared from the membrane (Fig. 1F), with a time-
dependent increase in the percentage of rLGALS9+ LAMP2+ lysosomes (Fig. 1G).  
 
rLGALS9 triggers vacuolization via PRKC-RAF1-MAP2K1-dependent 
clathrin-mediated internalization  
The treatment of MDCK and DLD-1 cells with rLGALS9 was characterized by the 
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progressive formation of large vacuoles (Fig. 2A), which affected ~95% of cells after 
24 h (Fig. 2B). Vacuole formation was blocked by cotreatment with α-lactose or 
blocking anti-LGALS9 antibody, but not by sucrose (Fig. 2A, B). Treatment of MDCK 
or DLD-1 cells on ice, at low pH, or with the DNM/dynamin GTPase inhibitor 
dynasore abrogated rLGALS9-mediated vacuole formation (Fig. 2C, D, Fig. S2A). 
Thus, rLGALS9 internalized via active clathrin-dependent endocytosis. To 
characterize the internalization pathway of rLGALS9, MDCK and DLD-1 cells were 
co-incubated with inhibitors of kinases involved in endocytosis. Among these, the 
PRKC-inhibitor UCN-01 dose-dependently reduced rLGALS9 uptake and 
vacuolization (Fig. 2E, Fig. S2A). UCN-01 also reduced colocalization of rLGALS9 
with early endosomes (Fig. S2B). In line with this, rLGALS9 treatment 
phosphorylated various PRKC isoforms, particularly atypical PRKC isoforms 
PRKCZ/PRKCζ and PRKCI/PRKCλ (Fig. 2F). Further, inhibition of RAF1/CRAF 
(GW5074), but not BRAF (Dabrafenib) strongly reduced rLGALS9-induced 
vacuolization in MDCK cells (Fig. 2G, Fig. S2A). Correspondingly, inhibition of 
downstream kinases MAP2K1 and MAP2K2 (U0126) also strongly inhibited rLGALS9 
internalization and vacuolization (Fig. 2G, Fig. S2A). To confirm the requirement for 
MAP2K-signaling, the predominant MEK isoform in DLD-1, MAP2K1, was knocked 
down by small interfering (si)RNA (Fig. S2C). Treatment of MAP2K1-deficient DLD-1 
cells with rLGALS9 did not induce vacuole formation (Fig. 2H, Fig. S2C). Thus, 
rLGALS9 is internalized via clathrin-dependent, PRKC-RAF1-MAP2K1-mediated 
endocytosis in nonpolarized MDCK cells and DLD-1 colorectal cancer cells, 
whereupon it triggers formation of large vacuoles.  
 
rLGALS9 has direct dose-dependent cytotoxic activity toward colon 
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carcinoma in vitro and in vivo 
Due to the progressive vacuolar swelling upon treatment with rLGALS9, the nuclear 
size of MDCK and DLD-1 cells was reduced by ~40% within 5 h (Fig. 3A, B). 
Treatment of MDCK and DLD-1 cells with rLGALS9 also dose-dependently triggered 
the apoptotic feature of phosphatidylserine (PS) surface exposure (Fig. 3C), loss in 
cell viability (Fig. 3D), reduced sphere formation (Fig. 3E) and reduced colony 
formation (Fig. 3F). This cytotoxic effect of rLGALS9 was inhibited by α-lactose, but 
not sucrose as illustrated for loss of cell viability and PS-exposure (Fig. 3G, Fig. 
S2D). The naturally occurring short and medium LGALS9 isoforms (rLGALS9[S] and 
rLGALS9[M]) also had cytotoxic effects towards DLD-1 cells, but at higher molar 
concentrations (Fig. 3H, Fig. S2E).  
In primary patient-derived colon carcinoma cells, treatment with rLGALS9 also 
induced numerous vacuoles (Fig. 3I), resulting in cellular detachment, PS-exposure 
(Fig. 3J, Fig. S2F) and reduced cell viability (Fig. 3K), which was inhibited by α-
lactose, but not sucrose (Fig. 3I-K). Treatment of mice bearing DLD-1 xenografts 
with rLGALS9 strongly inhibited tumor growth (Fig. 3L) and increased overall survival 
(Fig. 3M; 50% for rLGALS9 vs. 0% for control animals), with no detectable signs of 
toxicity, such as weight loss (Fig. 3N). Corresponding to the lack of toxicity in vivo, 
short-term ex vivo cultures of untransformed primary normal human colon epithelial 
cells were resistant to rLGALS9, with no vacuolization (Fig. 3O), PS-exposure (Fig. 
3P, Fig. S2F), and no loss in cell viability (Fig. 3P). 
 
rLGALS9 selectively induces cell death in KRAS mutant colon carcinoma 
cells 
From the data above it is evident that rLGALS9 triggers prominent cytotoxic effects in 
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DLD-1 colon carcinoma cells characterized by formation of large vacuoles that 
required RAF1 and MAP2K1 signaling. The cytotoxicity of rLGALS9 similarly 
depended on MAP2K1 and RAF1, as siRNA-mediated knockdown of either kinase 
strongly inhibited the cytotoxic effect of rLGALS9 on DLD-1 cells (Fig. 4A, Fig. S3A). 
In contrast, siRNA-mediated knockdown of BRAF did not affect rLGALS9 cytotoxity 
(Fig. 4A, Fig. S3A). Thus, rLGALS9-mediated RAF1, but not BRAF, signaling is 
required for cytotoxicity. Interestingly, previous studies demonstrated that RAF1 is 
responsible for transmitting signals from mutated KRAS to downstream kinases 
MAP2K1 and MAP2K2, whereas BRAF is not required.21 Further, knockdown of 
RAF1 inhibits tumorigenesis of KRAS mutant cells.22 To investigate whether the 
cytotoxic activity of rLGALS9 could similarly depend on KRAS mutation, a panel of 
colon carcinoma cell lines with either oncogenic KRAS or oncogenic BRAF mutation 
was analyzed. Overnight treatment with rLGALS9 induced PS-exposure and reduced 
cell viability in all KRASmut BRAFWT cells (Fig. 4B, C), but did not or only minimally 
affected cell viability of KRASWT BRAFmut cells. Similarly, rLGALS9 reduced colony 
formation in all KRASmut BRAFWT cell lines, but not in KRASWT BRAFmut cells (Fig. 
4D).  
Of note, Caco-2 cells that are both KRAS and BRAF wild-type (KRASWT 
BRAFWT) proved resistant to rLGALS9, whereas another KRASWT BRAFWT cell line, 
HCT-8, was sensitive to rLGALS9-mediated cell death (Fig. 4E). To identify a causal 
relationship between expression of a mutant KRAS allele and rLGALS9-mediated 
cytotoxicity, the rLGALS9 resistant KRASWT BRAFWT cell line Caco-2 was transduced 
with the KRASG12V oncogene (Caco-2.KRASG12V). In these Caco-2.KRASG12V cells, 
treatment with rLGALS9 proved cytotoxic, with vacuole formation, reduced cell 
viability and inhibited colony formation identical to that induced in other KRASmut 
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BRAFWT cell lines (Fig. 4F-H). Similarly, transduction of the rLGALS9 sensitive 
KRASWT BRAFWT cell line HCT-8 with the KRASG12V oncogene (HCT-8.KRASG12V) 
further sensitized these cells to rLGALS9 treatment. In contrast, the oncogenic BRAF 
mutant allele BRAFV600E (HCT-8.BRAFV600E) did not sensitize cells to rLGALS9 
treatment (Fig. 4I, J).  
rLGALS9 was previously reported to induce apoptosis in leukemic T-cells, 
multiple myeloma, Burkitt- and Hodgkin-lymphoma and melanoma cells.14,23 
However, rLGALS9 treatment of DLD-1 cells was not associated with 
CASP3/caspase-3 processing (Fig. 4K) nor did the pan-caspase inhibitor Z-VAD-fmk 
inhibit rLGALS9-induced vacuolization (Fig. 4L, Fig. S3B). Furthermore, cell death 
was not necrotic as cells displayed PS on the surface without membrane 
permeabilization after 6 h as assessed by propidium iodide (data not shown), nor was 
cell death inhibited by the necroptosis inhibitor necrostatin alone or in combination 
with Z-VAD-fmk (Fig. 4L, Fig. S3B). To corroborate the apoptosis-independent effect 
of rLGALS9, isogenic and apoptosis-resistant KRASG12V HCT116 cell lines with an 
oncogenic class III phosphatidylinositol 3-kinase (PtdIns3K) mutation or with a 
deficiency in the mitochondrial apoptosis regulator BAX (BCL2-associated X protein) 
were treated with rLGALS9. Both apoptosis-resistant lines remained sensitive to 
rLGALS9 cytotoxicity (Fig. 4M), but were resistant to apoptosis inducer 
TNFSF10/TRAIL (tumor necrosis factor [ligand] superfamily, member 10) (Fig. 4M). 
These data indicate that rLGALS9-induced cell death in colon cancer cells with a 
mutated KRAS allele is likely independent of apoptosis or necrosis. 
 
rLGALS9 induced cell death depends on basal autophagic flux and is 
associated with lysosomal swelling and autophagosome formation 
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The progressive accumulation of rLGALS9 within the lysosomal compartment was 
associated with marked swelling of LAMP2-positive lysosomes in KRASmut cells (Fig. 
5A, left panels), but not BRAFmut cells (Fig. S4A). This increase in lysosomal size 
was confirmed using LysoTracker-DND-99 (Fig. 5A, right panels), with signal 
intensity strongly increasing upon rLGALS9 treatment. This swelling of lysosomes 
was detected in all rLGALS9-sensitive, but not -resistant, cell lines (Fig. 5B). Of note, 
in the wild-type cell lines HCT-8 and Caco-2 the expression of KRASG12V increased 
the swelling of lysosomes upon rLGALS9 treatment (Fig. 5B). Conversely, the 
expression of BRAFV600E reduced lysosomal swelling in HCT-8 cells (Fig. 5B). This 
rLGALS9-induced swelling of lysosomes correlated with loss in cell viability (Fig. 5C). 
Of note, although the LysoTracker signal as well as the level of red fluorescence of 
acridine orange-stained cells increased over the first 6 h of treatment with rLGALS9, 
the signal intensity of both dyes was decreased after 24 h of treatment (Fig. S4B). 
Analysis of vacuolar diameter revealed that all vacuoles with a diameter >2.5 
nanometer in size lost their red acridine orange signal (Fig. S4B), indicating that 
these dilated lysosomes lost functionality.   
Based on the progressive vacuolization upon rLGALS9 treatment, we 
reasoned that autophagy might be involved. A hallmark feature of autophagy is the 
lipidation of MAP1LC3 B/LC3B (microtubule-associated protein 1 light chain 3) into 
LC3B-II. This LC3B-II is recruited to phagophore membranes yielding a punctate 
staining pattern. In rLGALS9-treated cells such LC3B puncta were clearly visible 
(Fig. 5D), indicative of autophagosome formation. Correspondingly, the staining 
intensity of monodansylcadaverine and Cyto-ID, both dyes that can be used to label 
autophagosomes, were increased in DLD-1 cells upon treatment with rLGALS9 (Fig. 
5D). This increase in autophagosomes correlated with a loss in cell viability upon 
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rLGALS9 treatment, as illustrated for cyto-ID (Fig. 5E). Upon treatment with 
rLGALS9, the levels of LC3B-II strongly increased in rLGALS9-sensitive KRASmut cell 
lines, MDCK and primary malignant colorectal cancer cells (Fig 5F, G, Fig. S4C). In 
contrast, LC3B-II levels did not increase in rLGALS9-resistant BRAFmut cell lines or 
KRASWT BRAFwWT Caco-2 cells (Fig. 5F, G), whereas LC3B-II levels did increase in 
Caco-2.KRASG12V cells (Fig. 5F, G, Fig. S4C). Of note, the formation of 
autophagosomes during rLGALS9 treatment did not require the autophagy regulator 
MTOR (mechanistic target of rapamycin [serine/threonine kinase]), as rLGALS9 
treatment induced both phosphorylation and dephosphorylation of MTOR in KRASmut 
and BRAFmut cell lines, with minimal effect on phosphorylation of the downstream 
MTOR target RPS6KB1 (ribosomal protein S6 kinase, 70kDa, polypeptide 1) (Fig. 
5H). 
To further characterize the role of autophagy in the cytotoxic effects of 
rLGALS9 in KRASmut colon cancer cells, DLD-1 cells were depleted for ATG5 
(autophagy related 5) or the upstream autophagy regulator BECN1/Beclin 1 using 
siRNA (Fig. S3A), which should block formation of autophagosomes. Indeed, in 
ATG5-depleted cells LC3B-I accumulated in the absence of conversion into LC3B-II 
upon rLGALS9 treatment, whereas in control siRNA conditions LC3B-II accumulation 
was detected (Fig. S4D). Importantly, ATG5 depletion strongly inhibited the cytotoxic 
activity of rLGALS9 towards DLD-1 cells (Fig. 5I). In line with this, siRNA-mediated 
depletion of BECN1 almost completely abrogated the cytotoxic effect of rLGALS9 
treatment in DLD-1 cells (Fig. 5J). Thus, inhibition of autophagosome formation 
inhibits rLGALS9-induced cell death of KRAS mutant colon cancer cells. 
Previously, oncogenic mutation of KRAS was shown to associate with 
increased levels of basal autophagy.24,25 Correspondingly, basal autophagic flux, as 
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determined by the accumulation of LC3B-II upon chloroquine treatment, was high in 
KRASmut and low in BRAFmut cell lines (Fig. 5K, Fig. S4E). In addition, the KRASWT 
BRAFWT and rLGALS9-sensitive cell line HCT-8 was characterized by high 
autophagic flux, whereas the KRASWT BRAFWT and rLGALS9-resistant cell line Caco-
2 was characterized by low autophagic flux. This basal autophagic flux strongly 
correlated with increases in LysoTracker signal as well as loss in cell viability upon 
rLGALS9 treatment (Fig. 5L, M). Thus, the basal autophagic flux in colon cancer 
cells determines the sensitivity toward rLGALS9 treatment. 
 
rLGALS9 induces dysfunctional autophagy halted at the stage of 
autophagosomal-lysosomal fusion  
During autophagy the accumulation of LC3B-II is typically transient and normalizes 
when autophagosomes fuse with lysosomes, due to degradation of the 
autolysosomal content. However, the progressive vacuolization upon rLGALS9 
treatment suggested that autophagy may be incompletely executed. To assess this 
possibility, the levels of LC3B-II and the ubiquitin-binding scaffold protein 
SQSTM1/p62 (sequestosome 1) were determined over time. Upon full execution of 
autophagy, e.g. upon rapamycin treatment of DLD-1 cells (Fig. 6A, B) and MDCK 
cells (Fig. S5A), both proteins were degraded after 24 h. However, the levels of 
LC3B-II and SQSTM1 remained elevated in cells treated with rLGALS9 after 24 h 
(Fig. 6A, B). These effects of rLGALS9 resembled those of the lysosomal inhibitor 
chloroquine (Fig. 6A, B) and were inhibited by α-lactose but not sucrose (Fig. S5B). 
Further time course analysis of SQSTM1 levels revealed an initial small decrease in 
the first hours of rLGALS9 treatment followed by SQSTM1 accumulation at later time 
points (Fig. 6C). This accumulation was observed in all KRASmut BRAFWT cell lines, 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 E
xe
ter
] a
t 2
3:3
3 1
8 J
un
e 2
01
5 
 - 14 - 
 
with an average fold increase in SQSTM1 levels of ~2.5 (Fig. 6D). In contrast, 
SQSTM1 levels did not change in KRASWT BRAFmut cells (Fig. 6D).  
The accumulation of LC3B-II and SQSTM1 suggest that rLGALS9-induced cell 
death is likely due to inhibition of autophagosome-lysosome fusion. As shown in 
Figure 1, rLGALS9 accumulated in lysosomes. In contrast, rLGALS9 overlap with 
autophagosomes as evaluated by treatment with rLGALS9-594 and counterstaining 
with LC3B was minimal in DLD-1 cells (Fig. 6E), with a corresponding low level of 
colocalization (Fig. 6F). Furthermore, the proteins LAMP2 and LC3B also did not 
colocalize in rLGALS9-treated cells, indicative of an arrest in the autophagic process 
at the stage of autophagosome-lysosome fusion (Fig. 6G). Of note, treatment with 
chloroquine triggered an analogous nonoverlapping LAMP2-LC3B staining pattern 
and Rr colocalization score (Fig. 6G). Arrested autophagy upon rLGALS9 treatment 
was confirmed using mCherry-GFP-LC3-transfected DLD-1 cells in which 
autophagosome-lysosome fusion will result in loss of GFP signal. Treatment of DLD-
1.mCherry-GFP-LC3 with rLGALS9 did not reduce GFP-signal intensity whereby the 
ratio of mCherry/GFP fluorescent signal did not change, similar to fluorescent LC3-
signal after treatment with chloroquine (Fig. 6H). Conversely, execution of autophagy 
in control settings in which DLD-1.mCherry-GFP-LC3 cells were serum starved 
strongly reduced the GFP-signal intensity and thereby increased the mCherry/GFP 
ratio (Fig. 6H, Fig. S5C).  
Taken together, rLGALS9 treatment induces lysosomal swelling and 
autophagosome formation in KRASmut colon carcinoma cells, which results in halted 
autophagy by the inhibition of autophagosome-lysosome fusion. Of note, this effect is 
similar as that induced by the lysosomal inhibitor chloroquine. Thus, rLGALS9 seems 
to act an oncogenic KRAS-selective lysosomal inhibitor that induces dysfunctional 
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autophagy and cell death. 
Discussion 
In this study we show that oncogenic mutation of KRAS sensitizes CRC cells to 
autophagy-dependent cell death by a recombinant form of the epithelial polarity 
regulator LGALS9 in vitro and in vivo. We propose a mode of action where rLGALS9 
undergoes rapid endosomal internalization in nonpolarized CRC cells and 
accumulates in the lysosomal compartment. In KRASmut CRC cells, exposure to 
rLGALS9 is characterized by lysosomal swelling, autophagosome formation and 
halted autophagosome-lysosome fusion, ultimately leading to cell death (Fig. 7). This 
sensitivity of KRASmut CRC for rLGALS9 is of potential clinical relevance, since 
KRASmut CRC cells are notoriously refractory to available therapies, and often 
acquire therapy resistance by elevating basal levels of autophagy.  
Treatment with rLGALS9 resulted in the accumulation of rLGALS9 in the 
lysosomal compartment and lysosomal swelling in KRASmut but not BRAFmut CRC 
cells. Furthermore, cell death induced by rLGALS9 correlated with an increase in 
levels of autophagosomes. In line with this, rLGALS9-induced cytotoxicity depended 
on the autophagic pathway, with ATG5 and BECN1 knockdown protecting against 
rLGALS9 cytotoxicity. However, the execution of autophagy upon treatment of 
KRASmut CRC with rLGALS9 was halted at the stage of autophagosome-lysosome 
fusion, leading to hallmark accumulation of LC3B-II and SQSTM1 over time. Such 
inhibition of autophagosome-lysosome fusion and LC3B-II-SQSTM1 accumulation 
has previously been reported for the lysosomal inhibitor chloroquine, leading to 
vacuolization and lysosomal swelling as identified here for rLGALS9.26,24 
Colocalization analysis clearly confirmed lysosomal accumulation of rLGALS9 and 
lack of association with autophagosomes. Thus, rLGALS9 seems to act as a 
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lysosomal inhibitor, similar to chloroquine, in KRASmut CRC. Of note, oncogenic 
KRAS mutation impairs normal lysosomal composition and function in CRC cells, 
which sensitizes these cells to lysosome-targeting drugs.27 
The differential sensitivity of KRASmut and BRAFmut cells to rLGALS9 was 
directly correlated with their levels of basal autophagic flux, with KRASmut cell lines 
having high and BRAFmut cells having low basal autophagic flux. In line with this, 
activated KRAS was previously shown to trigger so-called “autophagy addiction”, with 
autophagy being required for maintenance of metabolism and tumorigenesis.25,24,28 
Conversely, the low autophagic flux levels of BRAFmut cells seem to be specific for 
CRC, since BRAFmut cells have high basal autophagy levels in other types of cancer 
such as lung cancer29,30 and melanoma.31 The correlation between high basal 
autophagic flux levels and the sensitivity toward rLGALS9 treatment may be a logical 
consequence of the inhibited autophagosome-lysosome fusion that is induced by 
rLGALS9. By preventing normal execution of autophagy, rLGALS9 induces shortness 
of energy, which will eventually lead to cell death in such “autophagy addicted” 
cancers. In line with this, targeting autophagy has been postulated as a promising 
target to treat (RAS mutated) cancers with high basal autophagic flux.32 However, 
cancers which harbor RAS mutations are not always sensitive toward treatment with 
autophagy inhibitors, and the expression of oncogenic RAS may even promote 
resistance toward autophagy inhibition in lung cancer cell lines. 33 Therefore, the 
relation between KRASmut expression and sensitivity toward rLGALS9, may be 
specific for colon cancer.  
Besides the maintenance of tumorigenesis, the activation of autophagy is one 
of the mechanisms by which tumor cells acquire therapy resistance.34 Indeed, high 
autophagic flux is associated with poor prognosis and drug resistance in CRC,35  with 
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KRASmut CRC cells being notoriously refractory to available therapies, including 
EGFR-targeted therapeutics.2 Also in colon cancer stem cells, the autophagic 
pathway is responsible for the induction of resistance toward photodynamic therapy, 
which can be counteracted by the use of autophagy inhibitors.36 Similarly, elevated 
levels of basal autophagic flux are found in cervical cancers compared to healthy 
tissue, which is even further enhanced by cisplatin treatment.37 Interestingly, 
simultaneous treatment of ovarian cancers with cisplatin and autophagy inhibitors 
increases cell death.37 Similar synergistic effects of autophagy inhibitors and 
standard therapies have been found in many other cancer types.34 Hence, rLGALS9 
is not only of clinical relevance in its own right, but may be of particular relevance in 
combination therapies. Of note, we showed that apoptosis-resistant HCT116 strains 
with an oncogenic PtdIns3K mutation (found in ~15–20% of colon cancer patients in 
large population-based studies38,39) or BAX-deficiency remained sensitive to 
rLGALS9 cytotoxicity, while being resistant to the typical apoptosis-inducer 
TNFSF10/TRAIL. Thus, the autophagy-inhibiting effects of rLGALS9 may be clinically 
relevant for the treatment of autophagy addicted KRASmut colon cancers and to 
overcome intrinsic/acquired therapy resistance. 
Treatment with rLGALS9 did not negatively affect primary cultures of normal 
colonic epithelial cells, nor was treatment of xenografted mice with rLGALS9 
associated with detectable signs of toxicity. This differential sensitivity of normal 
versus malignant epithelial cells to rLGALS9 provides a promising therapeutic 
window. As galectins bind to glycosylated proteins and changes in glycosylation are a 
hallmark of cancer,40 cancer-specific glycosylation may have altered the receptor 
profile for rLGALS9. For instance, short and incomplete glycan structures to which 
rLGALS9 can bind, such as the Forssman antigen,41,12 have been reported in 
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CRC.42,43 Although rLGALS9 did not interact with this glycolipid on DLD-1 cells (data 
not shown), alternate cancer-specific and de novo glycoepitopes may account for the 
cancer-selective activity of rLGALS9. 
In contrast to the sensitivity of KRASmut CRC cells to rLGALS9, oncogenic 
mutation of BRAF proved to be associated with resistance to rLGALS9. 
Correspondingly, siRNA knockdown experiments in KRASmut DLD-1 cells 
demonstrated that rLGALS9 cytotoxicity did not require BRAF signaling, but was 
dependent on RAF1 and MAP2K1 signaling. This finding is in line with the reported 
requirement of oncogenic RAS for RAF1-, but not BRAF-, mediated activation of 
MAP2K.22,21,44,45 Indeed, although mutated KRAS and BRAF both activate 
MAP2K/mitogen-activated protein kinase kinases-MAPK/mitogen-activated protein 
kinase-signaling and disrupt polarity in colon epithelial cells,5 oncogenic KRAS and 
BRAF transformations typically occur in a mutually exclusive manner.46 Therefore, 
differences in sensitivity toward rLGALS9 treatment between KRAS and BRAF 
mutant CRC may rely on their respective signaling via RAF1 and BRAF. Of note, 
oncogenic KRAS signaling was reported to require heterodimerization between RAF1 
and BRAF,47 whereas oncogenic BRAFV600E signaling is activated through 
monomeric BRAF.48,49 It will be of interest to determine whether a differential 
requirement for homo- or heterodimerization of RAF1 proteins upon rLGALS9 
treatment underlies the differential sensitivity of KRASmut vs. BRAFmut CRC cells. 
rLGALS9 is also widely known for its immunomodulatory properties, most 
notably its inhibition of autoimmune T-cell responses (reviewed in 14). However, 
rLGALS9 treatment also enhances antitumor immunity in murine sarcoma and 
melanoma models, leading to prolonged survival.50,51 Further, rLGALS9 can induce 
activation and expansion of human T-cells ex vivo.52 Conversely, rLGALS9 promotes 
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escape from immune surveillance in Epstein Bar virus-infected nasopharyngeal 
carcinoma cells.53 Thus the possible stimulatory or inhibitory effects of rLGALS9 on 
antitumor immunity in KRASmut CRC will need to be evaluated to fully characterize 
the therapeutic potential of rLGALS9.  
In conclusion, the epithelial polarity regulator rLGALS9 has potent cytotoxic 
activity towards KRASmut colon cancer by the induction of frustrated autophagy. 
Therefore, rLGALS9 may be exploitable for therapeutic use in the treatment of 
refractory KRASmut cancers. 
Materials and Methods 
Cell lines and primary colorectal (cancer) cells  
MDCK, DLD-1, HCT116, HT29, LOVO, SW620, SW480, Caco-2, Colo205, HCT-8 
and WiDr were obtained from the American Type Culture Collection (CCL-34, CCL-
221, CCL-247, HTB-38, CCL-229, CCL-227, CCL-228, HTB-37, CCL-222, CCL-244, 
CCL-218). Cell line authenticity was confirmed using STR profiling (Baseclear, The 
Netherlands and Idexx Radil, USA). All cell lines were cultured in RPMI or DMEM 
(Lonza, Biowhittaker BE12-604F and BE12-155F) supplemented with 10% fetal calf 
serum (Hyclone Thermo Scientific, SV30160.03) at 37oC, in a humidified 5% CO2
 
atmosphere. Primary colorectal cancer cell cultures were obtained by mincing tumor 
tissue from surgical resection. Primary colonic epithelium was obtained from Tebu-
Bio (The Netherlands, 2-96115).  
 
LGALS9 and inhibitors 
Recombinant LGALS9 (rLGALS9) containing a truncated 2 amino acid interdomain 
linker (also known as Gal-9(0)) and the physiologically occurring short isoform of 
LGALS9, LGALS9(S)/Gal-9(S), were produced as described previously.20 For 
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confocal analysis, rLGALS9 was conjugated to DyLight® 594 following the 
manufacturer’s protocol (DyLight 594 NHS Ester; Piercenet, Thermo scientific, 
46412).  
The following inhibitors were used: α-lactose (Sigma Aldrich, L3625), sucrose 
(Merck Millipore, 107651), Dynasore (Sigma Aldrich, D7693), UCN-01 (Sigma 
Aldrich, U6508), U0126 (Sigma Aldrich, U120), GW5074 (Sigma Aldrich, G6416), 
necrostatin-1 (Sigma Aldrich, N9037), and Z-VAD-fmk (Calbiochem, 627610). 
Chloroquine was from the LC3B Antibody Kit for Autophagy (Life Technologies, 
L10382). LGALS9 blocking antibody was from GalPharma. 
 
Cell transfection and RNA interference 
Caco-2.KRASG12V, HCT-8.KRASG12V and HCT-8.BRAFV600E were generated by 
transfecting parental Caco-2 and HCT-8 cells with pBabe-Puro-KRAS G12V or 
pBabe-Puro-BRAF-V600E plasmid (Addgene,Plasmid 46746 and Plasmid 17544) 
using Fugene-HD (Promega, E2311). Stable cell lines were obtained by puromycin 
selection (Gibco/Life Technologies, A11138-03). DLD-1.mCherry-GFP-LC3 was 
obtained by transfecting DLD-1 cells with GFP-mCherry-LC3 (which was a kind gift of 
Prof. Andrew Thorburn, Dept. of Pharmacology, University of Colorado Cancer 
Center) and subsequent puromycin selection. 
For RNA interference experiments, cells were precultured in a 12-well plates 
at a density of 1x105 cells/well for 24 h, after which siRNA transfections were 
performed with Dharmafect-2 (Dharmacon, T-2002-01) following the manufacturer’s 
recommendations using a final concentration of 5 nM siRNA against BRAF (Origine, 
SR300470), RAF1/CRAF (Origene, SR303972), MAP2K1 (Origene, SR303761), 
BECN1 (Origene, SR305711) or ATG5 (Origene, SR306286). siRNA-transected cells 
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were maintained under 80% confluence, and used 96 h after transfection for 
experiments. Cell viability was determined after long-term treatment with rLGALS9 (7 
days). Efficiency of knockdown of the target protein was evaluated (96 h after 
transfection) by western blotting (see below) using anti-BRAF (Santa Cruz 
Biotechnology, sc-5284), anti- RAF1/CRAF (Sigma Aldrich, R5773), anti-MEK1/2 
(Cell Signaling Technology, 9122), anti-BECN1 (Origene, TA301471) and anti-ATG5 
(Cell Signaling Technology, 9980), and appropriate secondary HRP-conjugated 
antibodies (Dako, P0447 and P0448). 
 
Vacuolization experiments 
Cells were precultured in a 48-well plate at a density of 2-3x104 cells/well. 
Subsequently cells were treated with rLGALS9 in the presence or absence of pre-
incubated inhibitors. Imaging of cell vacuolization (minimal n=3) of different 
experimental conditions was determined by digital microscopy (Evos digital inverted 
microscope), and the degree of vacuolized cells per image was quantified. 
Percentages of vacuolized cells were calculated based on total cell counts. 
 
Cell viability assays 
For ANXA5/annexin-V staining, cells were pre-cultured in a 48-well plate at a density 
of 2-3x104 cells/well. Subsequently cells were treated with rLGALS9 for the indicated 
concentrations and time span, with or without inhibitors, and subsequently harvested 
using trypsin. ANXA5 staining was performed according to the manufacturer’s 
protocol (Immunotools, 31490013). In brief, cells were washed once with cold 
calcium binding buffer and resuspended in calcium buffer containing ANXA5-FITC. 
After incubation for 10 min at 4°C, PS exposure was analyzed by flow cytometry 
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using a BD Accuri C6 flow cytometer (BD Biosciences) and accessory CFlow Plus 
analysis software (BD Biosciences). 
For long-term viability assays, cells were precultured in a 48-well plate at a 
density of 1.5x104 cells/well. Subsequently, cells were treated with 300 nM rLGALS9 
in the presence or absence of 40 mM α-lactose or sucrose, and incubated for 96 h. 
Then MTS (CellTiter 96® AQueous One Solution Cell Proliferation; Promega, G3580) 
was added to the culture medium (10% [v/v]) and incubated at 37oC. A maximum 
death control was induced by treating cells with 20% v/v ethanol. MTS readout was 
performed by measuring absorbance at 490 nanometer (Versamax microplate 
reader, Molecular Devices). Absorbance of the maximum death control was 
subtracted from all values, and cell viability was calculated as percentage of medium 
control. 
 
Colony forming and sphere assays 
For colony-forming assays, cells were harvested as a single cell suspension using 
trypsin. BD Matrigel™ (Basement Membrane Matrix; BD bioscience, 354234) was 
thawed on ice, and RPMI medium supplemented with 10% v/v fetal calf serum was 
cooled down to 0oC. Per condition, cells were mixed to reach a final solution of 5x103 
cells in medium containing 3% v/v Matrigel and 300 nM rLGALS9 per well. All 
conditions were performed in triplicate. Then, cells were placed at 37oC resulting in 
solidification of the Matrigel, and incubated for 96 h. To quantify colony formation, 
pictures were taken (minimum of 3 fields of view (FOV) per well, Evos digital inverted 
microscope), and the number of colonies was counted. 
For sphere-forming assays, tumor cells (2 x103) were cultured in the absence 
or presence of the indicated concentrations of rLGALS9 in low adherent culture 
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plates (96-wells; Costar, CLS3474). To quantify colony formation, pictures were 
taken after 1 week of incubation (minimum 3 FOV per well, Evos digital inverted 
microscope), and the number of spheres was counted. 
 
Fluorescence microscopy  
To determine rLGALS9 uptake and transport, cells were precultured in 8-well 
borosilicate chamber slides (Lab-Tek II Chambered Coverglass w/Cover 1.5 8 Well; 
Thermo Scientific, NNU#155409-PK) at a density of 2 x 104 cells/well. Subsequently, 
cells were transduced with Bacmam CellLight® Fluorescent Protein Constructs 
RAB5A-GFP or RAB7A-GFP (Life Technologies, C10586 and C10588), and treated 
with DyLight-coupled rLGALS9 (rLGALS9-594). For other cell compartmental 
markers, cells were treated with rLGALS9-594 and counterstained with anti-LAMP2 
(Abcam, Ab37024) and appropriate secondary antibodies conjugated to Alexa Fluor-
488 (Life Technologies, A11034). For cell membrane staining, anti-EPCAM (Stem 
Cell Technologies, 10109) and secondary antibody conjugated to Alexa Fluor 488 
(Life Technologies, A11029) was used. Similar protocols were used in combination 
with various inhibitors. In the case of intracellular antibody staining, cells were fixed 
with 4% w/v paraformaldehyde (PFA) and nuclei were stained with DAPI (Sigma 
Aldrich, D9542). Live-cell imaging was performed on the Solamere Nipkow Confocal 
Live Cell Imaging system, whereas Z-stacks were obtained using a Leica SP8 
Confocal microscope. All fluorescence images and stacks were analyzed using 
ImageJ software (for colocalization analysis, the Pearson's Correlation plug-in was 
used) or Leica application suite. 
To determine the size of the nucleus, cells were precultured in a 48-well plate 
at a density of 2-3x104 cells/well and treated with rLGALS9. Subsequently, cells were 
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fixed with 4% PFA, and nuclei were stained using DAPI. After 3 washes with PBS, 
nuclei were evaluated by fluorescence microscopy (Leica) and nuclear size was 
determined using ImageJ particle analysis plug-ins. 
For acridine orange, monodansylcadaverine, LysoTracker staining and cyto-
ID, cells were precultured in a 48-well plate at a density of 2-3x104 cells/well. After 
treatment with rLGALS9, acridine orange (1 μg/ml, Sigma Aldrich, A9231), 
monodansylcadaverine (30 μM, Sigma Aldrich, 30432), LysoTracker® Red DND-99 
(1 μM, Life Technologies, L-7528) or cyto-IDhoechst/Hoechst (Cyto-ID autophagy 
detection kit; Enzo lifesciences, ENZ-51031-0050) was added to the culture medium 
and subsequently incubated for 30 min at 37oC. Excess dye was removed by 3 
repetitive washes using PBS. Each staining was visualized by fluorescence 
microscopy (Leica) and pictures of each condition were made (minimal n=3). The 
corrected total cell fluorescence (CTCF) of LysoTracker signal was determined using 
ImageJ software. To determine integrity of lysosomes/autophagosomes, cells were 
stained with acridine orange before rLGALS9 treatment. Of note, pseudocolors were 
used for all fluorescence microscopic images included in the paper. 
 
Western blot analysis and ELISAs 
Cells were precultured in 6-well plates at a density of 3x105. Subsequently, cells were 
treated with rLGALS9 (300 nM) or chloroquine (100 µM) for the indicated time span. 
Cell lysates were prepared using lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.2, 20 
nM EDTA, 20 nM EGTA, 1% NP-40 [Roche, 12879500], 0.1% SDS [Sigma, L6026]; 
containing Na3VO4 [Sigma, 450243] and protease inhibitor cocktail [Sigmafast; Sigma 
Aldrich, S8820]), and protein concentration was determined using the Bradford 
protein assay (Bio-Rad, 500-0006). For each sample, 15-30 µg total protein was 
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loaded onto SDS-PAGE gels (10, 12 or 15%) for electrophoresis. Subsequently 
proteins were transferred to a nitrocellulose membrane (Amersham Hybond ECL; GE 
Healthcare, RPN303D). After blocking in 5% (w/v) milk powder/PBS, proteins were 
detected using primary antibodies against PKCs (Phospho-PKC Antibody Sampler 
Kit; Cell Signaling Technology, 9921), LC3B (LC3B Antibody Kit for Autophagy, Life 
Technologies, L10382), CASP3/Caspase-3 (Cell Signaling Technology, 9665), 
phospho-MTOR (serine 2448; Abcam, Ab109268), or phospho-RPS6KB1/p70S6K1 
(threonine 389, Abcam, Ab126818) and appropriate secondary HRP-conjugated 
antibodies (Dako, P0448). ACTB/β-actin (Directly HRP-conjugated; Abcam, 
Ab49900) or TUBA/α-tubulin (Acetyl-TUBA, Directly HRP-conjugated, Cell Signaling 
Technology, (Lys40) (D20G3), 5335) staining were used to assess protein loading. 
Blots were developed using chemiluminescent substrate (SuperSignal West Dura, 
Thermo scientific, Life Technologies, 34075), and X-ray films (Super RX, Fujifilm, 
47410 19230) or analysis on the ChemiDoc MP system (Bio-Rad). Quantification of 
detected protein levels was performed using the ImageJ tool for gel analysis.  
 The lysates used for SQSTM1 ELISAs were prepared as described for 
western blot analysis. The SQSTM1 ELISAs were performed following the 
manufacturer’s protocol (Enzo Lifesciences, ADI-900-212-0001).  
 
In vivo animal experiment 
Experiments involving animals were approved by the Committee for Research and 
Animal Ethics of the UMCG. Male athymic mice (Hsd:AthymicNude-Foxn1nu, Harlan, 
The Netherlands) were housed in individual ventilated cages, with ad libitum 
sterilized water and food, in a 12 h/12 h day and night rhythm. After an 
acclimatization period of 1 week, subcutaneous tumors were inoculated by injecting 
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5X105 DLD-1 cells in 100 µl BD Matrigel™. Tumor growth was monitored by 
measuring tumor volume using a caliper (l·h·w·0.5234). When the tumor reached a 
mean volume of 0.1 cm3, animals were stratified over different groups (n=5 per 
group), and rLGALS9 treatment was started. Treatments with rLGALS9 or PBS 
control were performed 3 times a week by intraperitoneal injections. When the tumor 
reached a size of 1.5 cm3, animals were terminated.  
 
Statistical analysis 
Statistical analysis was performed by one-way ANOVA followed by Tukey-Kramer 
post-test or by two-sided Student’s t-test using Prism software. P<0.05 was defined 
as a statistically significant difference. Where indicated * = P<0.05; ** = P<0.01; *** = 
P<0.001. All graphs show average +/- standard deviation, unless stated otherwise. 
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Fig. 1. rLGALS9 is internalized via endosomes and accumulates in the lysosomes. 
(A) MDCK cells were treated with rLGALS9-594 in the presence or absence of α-
lactose (40 mM) or sucrose (40 mM) and confocal images were captured at 1 min, 1 
h and 2 h. (B) Maximum association of rLGALS9-594 with the cell surface of DLD-1 
cells at 5 min of incubation (arrows highlight colocalization). Here, DLD-1 cells were 
incubated with rLGALS9-594, stained with anti-EPCAM-488, fixed with 4% PFA, and 
subsequently stained with DAPI. (C) For confocal colocalization analysis with early 
endosomes, DLD-1 cells were transduced with Bacmam CellLight® Fluorescent 
Protein Construct RAB5A-GFP and incubated with rLGALS9-594 and Hoechst. 
Maximum colocalization was observed after 15 min (arrows highlight colocalization). 
(D) For confocal colocalization analysis with late endosomes, DLD-1 cells were 
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transduced with Bacmam CellLight® Fluorescent Protein Construct RAB7A-GFP and 
incubated with rLGALS9-594 and Hoechst. Maximum colocalization was observed 
after 45 min (arrows highlight colocalization). (E) For confocal colocalization analysis 
with the lysosomes, DLD-1 cells were treated with rLGALS9-594, fixed with 4% PFA, 
and costaining was performed using anti-LAMP2-488. Maximum colocalization was 
observed after 24 h. (F) Colocalization analysis of EPCAM and rLGALS9 in DLD-1 
cells, using Pearson's correlation as determined using ImageJ. Rr=1, perfect 
colocalization; Rr=0, random localization; Rr=-1, total exclusion. (G) Time-dependent 
increase in lysosomal association of rLGALS9 in DLD-1 cells, determined as the 
percentage of rLGALS9-positive lysosomes of total amount of lysosomes.  
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Fig. 2. rLGALS9 is internalized via clathrin-dependent endocytosis mediated by 
PRKC and MAP2K1. (A) MDCK cells were treated with rLGALS9 (300 nM) in the 
presence or absence of α-lactose (40 mM) or sucrose (40 mM) or blocking anti-
LGALS9 monoclonal antibody (mAb; 10 μg/ml). Representative light microscopy 
pictures were taken after 1 h of treatment. (B) Quantification of the percentage of 
cells having visible vacuoles in MDCK and DLD-1 cells upon 1 h treatment as 
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described in (A). (C) MDCK and DLD-1 cells were treated with rLGALS9 (300 nM) for 
respectively 1 h and 6 h at 37oC versus 0oC at pH 7 or pH 5, after which 
vacuolization was quantified. (D) MDCK and DLD-1 cells were pre-incubated for 1 h 
with the indicated concentrations of Dynasore (or DMSO solvent control), after which 
vacuolization induced by rLGALS9 (300 nM) was determined. (E) MDCK and DLD-1 
cells were pre-incubated for 1 h with the indicated concentrations of UCN-01 after 
which vacuolization induced by rLGALS9 (300 nM) was determined. Representative 
fluorescent pictures (using rLGALS9-594) illustrate the cellular distribution of 
rLGALS9. (F) Western blot detection of different PRKC isoforms in rLGALS9 (300 
nM) treated MDCK cells. (G) MDCK cells were pretreated with RAF1 inhibitor 
GW5074 (50 μM, 48 h pre-incubation), BRAF inhibitor Dabrafenib (200 nM, 48 h pre-
incubation), and MAP2K inhibitor U0126 (100 μM, 2 h pre-incubation) and 
subsequently treated with rLGALS9 (300 nM), after which the percentage of cells with 
visible vacuoles was quantified. Representative fluorescence pictures (using 
rLGALS9-594) illustrate the cellular distribution of rLGALS9 with or without U0126 
pretreatment. (H) MAP2K1-deficient DLD-1 cells were treated with rLGALS9 for 6 h 
after which vacuole formation was quantified.  
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Fig. 3. Dose-dependent cytotoxicity of rLGALS9 in vitro and in vivo (A) DAPI staining 
visualized the nucleus in medium- and rLGALS9-treated (5 h, 300 nM) MDCK cells. 
(B) Quantification of nuclear size of MDCK and DLD-1 cells after 1- to 5-h treatment 
with rLGALS9 (300 nM). (C) MDCK and DLD-1 cells were treated with the indicated 
concentrations of rLGALS9 and analyzed for PS exposure by flow cytometric ANXA5 
staining. (D) As in (C), but analyzed for viability after 48 h with the MTS assay. (E) 
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MDCK and DLD-1 cells were plated on nonadherent plates and treated with the 
indicated concentrations of rLGALS9. The number of tumor spheres was quantified 
by counting 3 fields-of-view in triplicates after 1 week. (F) MDCK and DLD-1 cells 
were plated in Matrigel and treated with the indicated concentrations of rLGALS9. 
After 1 week, colony formation was quantified by counting 3 fields-of-view in 
triplicates. (G) Analysis of cell viability after 48 h treatment of MDCK and DLD-1 cells 
with rLGALS9 (300 nM) +/- α-lactose or sucrose (40 mM). (H) Cell viability of DLD-1 
cells after 48 h of treatment with increasing doses of rLGALS9/GAL9[0], rLGALS9[S], 
or rLGALS9[M]. (I) Representative light microscopy pictures of primary patient-
derived colorectal cancer cells detailing vacuole formation after 3 h treatment with 
rLGALS9 (300 nM). (J) Analysis of PS exposure after 24 h treatment of primary 
patient-derived colorectal cancer cells with rLGALS9 (300 nM) in the presence or 
absence of α-lactose (40 mM). (K) Analysis of cell viability after 48 h treatment of 
primary patient-derived colorectal cancer cells with rLGALS9 alone or with rLGALS9 
and α-lactose or sucrose (40 mM). (L) Tumor growth of DLD-1 xenografts treated 
with rLGALS9. In brief, athymic nude mice were subcutaneously injected with 5x105 
DLD-1 cells in Matrigel. Treatment was started after tumor size reached 100 mm3 
and comprised 3 times/week intraperitoneal injection of rLGALS9 at the indicated 
doses. After 3 weeks, treatment was stopped and survival was determined. 
Average+/-SEM (M) Kaplan Meyer curve of survival of DLD-1 xenografted mice 
treated with the indicated concentrations rLGALS9 or solvent control. (N) Weight of 
rLGALS9-treated mice during the experiment. (O) Representative light microscopy 
pictures of primary normal colonic epithelial cells with rLGALS9 (300 nM) after 24 h. 
(P) Analysis of PS exposure after 6 h and cell viability after 48 h of treatment of 
primary normal colonic epithelial cells with 300 nM rLGALS9. 
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Fig. 4. KRAS mutant but not BRAF mutant colon cancer cell lines are sensitive to 
rLGALS9 treatment. (A) DLD-1 cells subjected to control siRNA or siRNA-mediated 
knockdown of MAP2K1, RAF1 or BRAF were treated with 300 nM rLGALS9 for 1 
week, after which cell viability was determined by the MTS assay. (B) A panel of 
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colon carcinoma cell lines with KRAS mutation (KRASmut) or BRAF mutation 
(BRAFmut) were treated with 300 nM rLGALS9 for 24 h and analyzed for PS 
exposure. (C) As in (B), but analyzed after 48 h for cell viability with the MTS assay. 
(D) Colon cancer cell lines were plated in Matrigel and treated with 300 nM rLGALS9. 
After 72 h, colony formation was quantified by counting 3 fields-of-view in triplicate. 
(E) KRASWT BRAFWT tumor cell lines Caco-2 and HCT-8 were treated with 300 nM 
rLGALS9 and analyzed for PS exposure (24 h) and cell viability (48 h). (F-H) The 
rLGALS9-resistant cell line Caco-2 (KRASWT BRAFWT) was transfected with plasmid 
encoding KRAS containing the G12V activating mutation. The resulting cell line 
Caco-2.KRASG12V was analyzed for (F) vacuole formation (G) cell viability and (H) 
colony formation after treatment with rLGALS9 for 3, 24, 48, and 72 h. (I-J) The 
rLGALS9-sensitive cell line HCT-8 (KRASWT BRAFWT) was transfected with plasmid 
encoding KRAS containing the G12V activating mutation or BRAF containing the 
V600E activating mutation. The resulting cell lines HCT-8.KRASG12V and HCT-
8.BRAFV600E were analyzed for (I) vacuole formation and (J) dose-dependent 
reduction in cell viability. (K) DLD-1 cells were treated with rLGALS9 (300 nM, 24 h) 
and cell lysates were analyzed by western blot for CASP3 (full-length/cleaved). (L) 
MDCK and DLD-1 cells were pre-incubated with the pan-caspase inhibitor Z-VAD-
fmk (20 μM), the necroptosis inhibitor necrostatin (100 μM) or Z-VAD-
fmk+necrostatin and analyzed for rLGALS9-induced vacuolization. (M) Parental 
HCT116, HCT116.PtdIns3K.WT, HCT116.PtdIns3K.MUT and HCT116.BAX-/- were 
treated with 300 nM rLGALS9 or 100 ng/ml recombinant human TNFSF10/TRAIL for 
24 h, after which cells were analyzed for PS exposure using flow cytometric ANXA5 
staining.  
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Fig. 5. rLGALS9-induced cell death is associated with lysosomal swelling and 
autophagosome formation. (A) Medium control and rLGALS9 (300 nM)-treated DLD-
1 cells were stained with anti-LAMP2 (left panel) or the lysosomal marker 
LysoTracker® Red DND-99. (B) Quantification of the change in LysoTracker signal 
upon 6 h treatment with 300 nM rLGALS9 of KRASmut cell lines (n=5), BRAFmut (n=3), 
Caco-2WT and Caco-2.KRASG12V, HCT-8WT, HCT-8.KRASG12V and HCT-8.BRAFV600E. 
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rLGALS9-induced lysosomal swelling was quantified by determining fluorescent 
signal induction using ImageJ (factor= rLGALS9/medium). (C) Linear correlation 
analysis of the reduction in cell viability upon rLGALS9 treatment and increases in 
LysoTracker signal upon rLGALS9 treatment. Dotted lines represent the 95% 
confidence interval. (D) Medium control and rLGALS9 (300 nM) treated DLD-1 cells 
were stained with anti-LC3B (left panel), monodansylcadaverine (MDC, middle 
panel), or Cyto-ID (left panel). All these stains detect autophagosomes. (E) Linear 
correlation analysis of the reduction in cell viability upon rLGALS9 treatment and 
increases in Cyto-ID signal upon rLGALS9 treatment. Dotted lines represent the 95% 
confidence interval. (F) A colon cancer cell panel was treated with rLGALS9 (300 nM) 
for different time points, after which cell lysates were subjected to western blot 
analysis to detect the lipidated form of LC3B (LC3B-II). (G) Quantification of the fold 
increase in LC3B-II induced by rLGALS9 in KRASmut cell lines (n=5), BRAFmut (n=3), 
Caco-2WT and Caco-2.KRASG12V (factor= rLGALS9/medium). (H) Western blot 
analysis of MTOR phosphorylation (serine 2448) and RPS6KB1/p70S6K1 
phosphorylation (threonine 389) in KRASmut and BRAFmut cell lines after treatment 
with 300 nM rLGALS9 for 6 h. (I) DLD-1 cells were subjected to control siRNA or 
siRNA-mediated knockdown of ATG5 and treated for 1 week with rLGALS9, after 
which cell viability was determined using the MTS assay. (J) DLD-1 cells were 
subjected to control siRNA or siRNA-mediated knockdown of BECN1 and treated for 
1 week with rLGALS9, after which cell viability was determined using the MTS assay. 
(K) Basal autophagic flux as determined by LC3B-II accumulation upon chloroquine 
treatment (6 h, 100 µM) in KRASmut cell lines (n=3), BRAFmut (n=2), Caco-2 and 
HCT8. (L) Linear correlation analysis of the increase in LysoTracker signal upon 
rLGALS9 treatment and basal autophagic flux as determined by chloroquine 
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treatment (6 h, 100 µM) (Fig. S3F). Dotted lines represent the 95% confidence 
interval. (M) Linear correlation analysis of the decrease in cell viability upon rLGALS9 
treatment and basal autophagic flux as determined by 6 h chloroquine treatment. 
Dotted lines represent the 95% confidence interval.  
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Fig. 6. Lysosomal accumulation of rLGALS9 results in halted autophagy. (A) LC3B-II 
levels after 24 h treatment of the indicated cell lines with rLGALS9 (300 nM), 
autophagy inhibitor chloroquine (100 μM) or autophagy inducer rapamycin (100 nM). 
(B) Analysis of SQSTM1 levels using ELISA after treatment of DLD-1 as in (A) 
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(factor= rLGALS9/medium). (C) Time-course analysis of SQSTM1 levels in DLD-1 
cells treated with rLGALS9 (24 h, 300 nM). (D) SQSTM1 formation induced by 
rLGALS9 treatment (24 h, 300 nM) in a panel of KRASmut cell lines (n=5) and 
BRAFmut (n=5). (E) Confocal microscopy pictures of DLD-1 cells treated for 24 h with 
DyLight-594-labeled rLGALS9 and costained with anti-LC3B-488. (F) LC3B/rLGALS9 
colocalization was analyzed by Pearson's correlation. (G) Confocal microscopy 
pictures of DLD-1 cells treated with rLGALS9 (24 h, 300 nM) or chloroquine (24 h, 
100 μM) and subsequently stained with anti-LAMP2 and anti-LC3B. LAMP2/LC3B 
colocalization was analyzed by Pearson's correlation. (H) Confocal microscopy 
pictures of DLD-1 cells transfected with a mCherry-GFP-LC3 construct treated with 
rLGALS9 (24 h, 300 nM) or chloroquine (24 h, 100 µM). mCherry/GFP ratio was 
analyzed using ImageJ software.  
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Fig. 7. rLGALS9 internalization and signaling in CRC. (A) Internalization route of 
rLGALS9 in polarized epithelial cells. (B) Cell death pathway in nonpolarized KRAS 
mutant colon carcinoma cells.  
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